Kazia Registers 232,956 ADS Offering Alongside 100% TNBC Clinical Benefit Data
KZIA has more than doubled off its 52-week low of $4.86 on elevated volume (4.4× avg).
Summary
Kazia registered a 232,956 ADS offering (116.5M ordinary shares) alongside positive Phase 1b TNBC data showing 100% clinical benefit. The offering is materially larger than the 95,110 ADSs disclosed in the concurrent filing.
Key Events · Financing and Capital Events · KZIA
-
232,956 ADS Offering Registered
The prospectus supplement registers 232,956 ADSs representing 116,478,000 ordinary shares — a materially larger offering than the 95,110 ADSs (47,555,000 ordinary shares) disclosed in the concurrent 424B3 filing.
-
100% Clinical Benefit in TNBC
All six evaluable Stage IV TNBC patients showed clinical benefit: 1 complete response, 4 partial responses, 1 stable disease (83% objective response rate), with no paxalisib-related serious adverse events.
-
Offering Terms and Reference Price
The last reported sale price was $14.60 per ADS on August 26, 2026. Leerink Partners and Guggenheim Securities are acting as placement agents. The offering is being conducted under Registration Statement No. 333-290598.
-
Dilution Impact
The company had approximately 14.1 million ADSs outstanding on a fully diluted basis. The 232,956 ADS offering represents a significant increase in share count, though the company had ~US$46M cash with runway into 2029, suggesting an opportunistic raise.
Analysis · KZIA · Life Sciences
A prospectus supplement filed by Kazia registers 232,956 American Depositary Shares, representing 116,478,000 ordinary shares — a materially larger offering than the 95,110 ADSs disclosed in the concurrent 424B3 filing. The filing also attaches the August 27, 2026 Form 6-K reporting 100% clinical benefit in six evaluable Stage IV TNBC patients treated with paxalisib, including one durable complete metabolic response. Leerink Partners and Guggenheim Securities are conducting the offering. The last reported sale price was $14.60 per ADS on August 26, 2026, versus today's price of $13.00. With approximately 14.1 million ADSs outstanding on a fully diluted basis, this offering represents a significant increase in share count. The clinical data is highly encouraging — 83% objective response rate with no treatment-related serious adverse events — but the offering itself is dilutive to existing shareholders. The company had approximately US$46 million in cash at year-end 2025 with runway into 2029, so this raise appears opportunistic rather than distress-driven, likely capitalizing on the positive data to fund expansion into HR+/HER2- breast cancer, early-stage TNBC, and pMMR CRC.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.6% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KZIA was trading at $13.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.8M. The 52-week trading range was $4.86 to $17.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.